vs
莫德纳(MRNA)与RPM INTERNATIONAL INC(RPM)财务数据对比。点击上方公司名可切换其他公司
RPM INTERNATIONAL INC的季度营收约是莫德纳的1.9倍($1.9B vs $1.0B),RPM INTERNATIONAL INC净利率更高(8.4% vs -19.7%,领先28.1%),RPM INTERNATIONAL INC同比增速更快(3.5% vs -45.4%),RPM INTERNATIONAL INC自由现金流更多($296.4M vs $-880.0M),过去两年RPM INTERNATIONAL INC的营收复合增速更高(12.0% vs -45.0%)
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业,深耕RNA治疗领域,核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA(mRNA)分子拷贝传递蛋白合成指令以触发人体免疫反应,公司名称由“修饰”“RNA”与“现代”三个词组合而来。
BVS娱乐前身为Saban制作、Saban国际及Saban娱乐,是华特迪士尼公司旗下子公司。1980年4月24日由哈伊姆·萨班与舒基·利维创立,最初主营音乐制作,后逐步转向电视节目制作发行业务,最为知名的是为Fox Family/ABC Family及已停播的Fox Kids、Jetix频道制作发行儿童节目。
MRNA vs RPM — 直观对比
营收规模更大
RPM
是对方的1.9倍
$1.0B
营收增速更快
RPM
高出48.9%
-45.4%
净利率更高
RPM
高出28.1%
-19.7%
自由现金流更多
RPM
多$1.2B
$-880.0M
两年增速更快
RPM
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q2 FY2026
| 指标 | ||
|---|---|---|
| 营收 | $1.0B | $1.9B |
| 净利润 | $-200.0M | $161.2M |
| 毛利率 | 79.6% | 40.8% |
| 营业利润率 | -25.6% | 11.0% |
| 净利率 | -19.7% | 8.4% |
| 营收同比 | -45.4% | 3.5% |
| 净利润同比 | -1638.5% | -12.0% |
| 每股收益(稀释后) | $-0.51 | $1.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
MRNA
RPM
| Q4 25 | — | $1.9B | ||
| Q3 25 | $1.0B | $2.1B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $966.0M | $1.8B | ||
| Q3 24 | $1.9B | $2.0B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.5B |
净利润
MRNA
RPM
| Q4 25 | — | $161.2M | ||
| Q3 25 | $-200.0M | $227.6M | ||
| Q2 25 | — | $225.8M | ||
| Q1 25 | — | $52.0M | ||
| Q4 24 | $-1.1B | $183.2M | ||
| Q3 24 | $13.0M | $227.7M | ||
| Q2 24 | — | $180.6M | ||
| Q1 24 | — | $61.2M |
毛利率
MRNA
RPM
| Q4 25 | — | 40.8% | ||
| Q3 25 | 79.6% | 42.3% | ||
| Q2 25 | — | 42.4% | ||
| Q1 25 | — | 38.4% | ||
| Q4 24 | 23.5% | 41.4% | ||
| Q3 24 | 72.4% | 42.5% | ||
| Q2 24 | — | 41.4% | ||
| Q1 24 | — | 39.9% |
营业利润率
MRNA
RPM
| Q4 25 | — | 11.0% | ||
| Q3 25 | -25.6% | 14.1% | ||
| Q2 25 | — | 11.9% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | -129.0% | 11.5% | ||
| Q3 24 | -3.8% | 14.8% | ||
| Q2 24 | — | 11.9% | ||
| Q1 24 | — | 5.5% |
净利率
MRNA
RPM
| Q4 25 | — | 8.4% | ||
| Q3 25 | -19.7% | 10.8% | ||
| Q2 25 | — | 10.8% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | -115.9% | 9.9% | ||
| Q3 24 | 0.7% | 11.6% | ||
| Q2 24 | — | 9.0% | ||
| Q1 24 | — | 4.0% |
每股收益(稀释后)
MRNA
RPM
| Q4 25 | — | $1.26 | ||
| Q3 25 | $-0.51 | $1.77 | ||
| Q2 25 | — | $1.76 | ||
| Q1 25 | — | $0.40 | ||
| Q4 24 | $-2.91 | $1.42 | ||
| Q3 24 | $0.03 | $1.77 | ||
| Q2 24 | — | $1.40 | ||
| Q1 24 | — | $0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $316.6M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $9.3B | $3.1B |
| 总资产 | $12.1B | $7.9B |
| 负债/权益比越低杠杆越低 | — | 0.80× |
8季度趋势,按日历期对齐
现金及短期投资
MRNA
RPM
| Q4 25 | — | $316.6M | ||
| Q3 25 | $1.1B | $297.1M | ||
| Q2 25 | — | $302.1M | ||
| Q1 25 | — | $241.9M | ||
| Q4 24 | $1.9B | $268.7M | ||
| Q3 24 | $1.6B | $231.6M | ||
| Q2 24 | — | $237.4M | ||
| Q1 24 | — | $248.9M |
总债务
MRNA
RPM
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.0B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.2B |
股东权益
MRNA
RPM
| Q4 25 | — | $3.1B | ||
| Q3 25 | $9.3B | $3.1B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | $10.9B | $2.7B | ||
| Q3 24 | $11.9B | $2.6B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.3B |
总资产
MRNA
RPM
| Q4 25 | — | $7.9B | ||
| Q3 25 | $12.1B | $7.9B | ||
| Q2 25 | — | $7.8B | ||
| Q1 25 | — | $6.6B | ||
| Q4 24 | $14.1B | $6.7B | ||
| Q3 24 | $15.8B | $6.6B | ||
| Q2 24 | — | $6.6B | ||
| Q1 24 | — | $6.4B |
负债/权益比
MRNA
RPM
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 0.79× | ||
| Q1 24 | — | 0.93× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-847.0M | $345.7M |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $296.4M |
| 自由现金流率自由现金流/营收 | -86.6% | 15.5% |
| 资本支出强度资本支出/营收 | 3.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 2.14× |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $582.9M |
8季度趋势,按日历期对齐
经营现金流
MRNA
RPM
| Q4 25 | — | $345.7M | ||
| Q3 25 | $-847.0M | $237.5M | ||
| Q2 25 | — | $149.2M | ||
| Q1 25 | — | $91.5M | ||
| Q4 24 | $825.0M | $279.4M | ||
| Q3 24 | $-1.6B | $248.1M | ||
| Q2 24 | — | $181.2M | ||
| Q1 24 | — | $173.4M |
自由现金流
MRNA
RPM
| Q4 25 | — | $296.4M | ||
| Q3 25 | $-880.0M | $175.0M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $33.3M | ||
| Q4 24 | $303.0M | $229.5M | ||
| Q3 24 | $-1.7B | $197.3M | ||
| Q2 24 | — | $105.3M | ||
| Q1 24 | — | $124.6M |
自由现金流率
MRNA
RPM
| Q4 25 | — | 15.5% | ||
| Q3 25 | -86.6% | 8.3% | ||
| Q2 25 | — | 3.8% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 31.4% | 12.4% | ||
| Q3 24 | -92.2% | 10.0% | ||
| Q2 24 | — | 5.2% | ||
| Q1 24 | — | 8.2% |
资本支出强度
MRNA
RPM
| Q4 25 | — | 2.6% | ||
| Q3 25 | 3.2% | 3.0% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | 54.0% | 2.7% | ||
| Q3 24 | 8.1% | 2.6% | ||
| Q2 24 | — | 3.8% | ||
| Q1 24 | — | 3.2% |
现金转化率
MRNA
RPM
| Q4 25 | — | 2.14× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 0.66× | ||
| Q1 25 | — | 1.76× | ||
| Q4 24 | — | 1.53× | ||
| Q3 24 | -120.46× | 1.09× | ||
| Q2 24 | — | 1.00× | ||
| Q1 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
RPM
| Construction Products Group Segment | $737.4M | 39% |
| Consumer Segment | $638.6M | 33% |
| Performance Coatings Group Segment | $533.8M | 28% |